ストックスクリーナーアプリを入手
2.13
4.48%
-0.10
アフターアワーズ：
2.15
0.02
+0.94%
前日終値:
$2.23
開ける：
$2.25
24時間の取引高:
381.22K
Relative Volume:
0.83
時価総額：
$41.51M
収益：
-
当期純損益:
$-40.94M
株価収益率:
-0.5547
EPS:
-3.84
ネットキャッシュフロー:
$-22.97M
1週間 パフォーマンス:
-21.98%
1か月 パフォーマンス:
-59.20%
6か月 パフォーマンス:
-77.84%
1年 パフォーマンス:
-79.08%
1日の値動き範囲:
$2.105
$2.2687
1週間の範囲:
$2.08
$2.77
52週間の値動き範囲:
$2.08
$20.00
Annovis Bio Inc Stock (ANVS) Company Profile
名前
Annovis Bio Inc
セクター
電話
484-875-3192
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
ANVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.13 | 41.51M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-10-25 | アップグレード | Maxim Group | Hold → Buy |
| 2023-12-29 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
Annovis Bio Inc (ANVS) 最新ニュース
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio stock hits 52-week low at $2.42 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio stock hits 52-week low at $2.42 amid market challenges - Investing.com
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Inside Annovis's Groundbreaking Alzheimer's Trial: CEO Opens Direct Dialogue With Patients - StockTitan
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline - MSN
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio stock hits 52-week low at $2.59 amid sharp decline By Investing.com - Investing.com South Africa
Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference - MSN
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap - MSN
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial - MSN
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN
Annovis Bio Inc. CEO to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on Pivotal Phase 3 Trial Progress - Nasdaq
Annovis to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - Hamilton Spectator
Annovis begins treatment of subjects in Alzheimer’s trial - Yahoo Finance
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial By Investing.com - Investing.com Australia
Annovis Bio announces first patients entered Phase 3 study of buntanetap - Yahoo Finance
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
Annovis Bio stock hits 52-week low at $4.05 amid market challenges - MSN
Annovis Bio sets terms for $21 million public offering - MSN
Annovis Bio completes $21 million stock and warrant offering - MSN
Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease - Marketscreener.com
Annovis Bio Launches Phase 3 Alzheimer’s Study - TipRanks
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease - Quantisnow
Annovis Bio completes $21 million stock and warrant offering By Investing.com - Investing.com South Africa
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - GlobeNewswire
Alzheimer's Drug Developer Annovis Secures Critical $21M Funding for Final-Stage Trial - StockTitan
Annovis Bio stock dips after pricing $21M securities offering - MSN
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Annovis Bio Prices $21 Million Public Offering; Shares Fall Sharply -February 03, 2025 at 11:56 am EST - Marketscreener.com
Annovis Bio Inc (ANVS) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):